Cue Biopharma Q3 net loss widens on higher R&D costs
CUE•
CUE•Cue Biopharma’s third-quarter revenue fell sharply year over year to $132,000, while its net loss widened to $50.02 million, with higher R&D and G&A expenses. The company reported positive Phase 2 results for CUE-221 and began dosing in a Phase 1 trial of CUE-401.
Cue Biopharma reported third-quarter revenue of $132,000, down sharply year over year because less revenue was recognized under its BI Collaboration and License Agreement as activities progressed. Net loss widened to $50.02 million, and operating expenses were $47.23 million. The company said R&D expenses rose with higher clinical trial costs and that R&D and G&A expenses also increased due to non-cash stock-based compensation.
The company reported positive Phase 2 results for CUE-221 and said it expects to advance the food allergy clinical program following FDA clearance. It also began dosing in a first-in-human Phase 1 trial of CUE-401 for autoimmune disease and is pursuing half-life extension for CUE-221.